Micro Rna 22 (Mirna22) And Breast Cancer:A Review
European Journal of Molecular & Clinical Medicine,
2022, Volume 9, Issue 7, Pages 9045-9053
AbstractWHO has reported that, 2.3 million women were diagnosed with breast cancer in 2021 and 685000 deaths occur globally due to breast cancer. As estimated at the end of 2020, there were 7.8 million women diagnosed with breast cancer in the past 5 years were alive, making it the world’s most prevalent cancer. Breast cancer is the most common cancer type in Indian female, and many patients suffer from recurrences and metastasis. There is no marker to predict the severity and invasiveness of breast cancer. Single-stranded, non-coding RNA molecules called microRNAs (miRNAs) control the expression of target genes through post-transcriptional alterations . Numerous studies suggested that miRNA has a promising role in the diagnosis and prognosis of various malignancies. In a number of malignancies, including gastric cancer, esophageal squamous cell carcinoma, breast cancer, and prostatic cancer, miR-22 is aberrantly expressed either up or down. miRNA-22 may be used a diagnostic as well as prognostic marker for breast cancer.
- Article View: 7
- PDF Download: 9